ZA200205145B - Thienopyridine derivatives, their production and use. - Google Patents
Thienopyridine derivatives, their production and use. Download PDFInfo
- Publication number
- ZA200205145B ZA200205145B ZA200205145A ZA200205145A ZA200205145B ZA 200205145 B ZA200205145 B ZA 200205145B ZA 200205145 A ZA200205145 A ZA 200205145A ZA 200205145 A ZA200205145 A ZA 200205145A ZA 200205145 B ZA200205145 B ZA 200205145B
- Authority
- ZA
- South Africa
- Prior art keywords
- optionally substituted
- group
- salt
- optionally
- ring
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 102
- 150000003839 salts Chemical class 0.000 claims description 76
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000004434 sulfur atom Chemical group 0.000 claims description 24
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 17
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
- -1 thiocarbamoyl group Chemical group 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 16
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- 239000000470 constituent Substances 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 206010003246 arthritis Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 150000001555 benzenes Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 6
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000006386 Bone Resorption Diseases 0.000 claims description 4
- 230000024279 bone resorption Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000016396 cytokine production Effects 0.000 claims description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical compound O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000105770 | 2000-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205145B true ZA200205145B (en) | 2003-09-04 |
Family
ID=18619051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205145A ZA200205145B (en) | 2000-02-29 | 2002-06-26 | Thienopyridine derivatives, their production and use. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6653476B2 (de) |
| EP (1) | EP1259515B1 (de) |
| JP (1) | JP3917821B2 (de) |
| KR (1) | KR100780584B1 (de) |
| CN (1) | CN1326859C (de) |
| AR (1) | AR028511A1 (de) |
| AT (1) | ATE282042T1 (de) |
| AU (1) | AU2001235985A1 (de) |
| BR (1) | BR0108840A (de) |
| CA (1) | CA2397165A1 (de) |
| CZ (1) | CZ20022511A3 (de) |
| DE (1) | DE60107055T2 (de) |
| DK (1) | DK1259515T3 (de) |
| ES (1) | ES2227139T3 (de) |
| HK (1) | HK1048120B (de) |
| HU (1) | HUP0300028A3 (de) |
| IL (1) | IL151082A0 (de) |
| MX (1) | MXPA02008414A (de) |
| NO (1) | NO20024107L (de) |
| NZ (1) | NZ520155A (de) |
| PL (1) | PL358015A1 (de) |
| PT (1) | PT1259515E (de) |
| RU (1) | RU2002125854A (de) |
| SI (1) | SI1259515T1 (de) |
| SK (1) | SK10712002A3 (de) |
| TW (1) | TW591031B (de) |
| WO (1) | WO2001064685A2 (de) |
| ZA (1) | ZA200205145B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW591031B (en) * | 2000-02-29 | 2004-06-11 | Takeda Chemical Industries Ltd | Thienopyridine derivatives, their production and use |
| US7644057B2 (en) * | 2001-01-03 | 2010-01-05 | International Business Machines Corporation | System and method for electronic communication management |
| WO2003018590A1 (fr) * | 2001-08-24 | 2003-03-06 | Takeda Chemical Industries, Ltd. | Procede de production d'un derive de la thienopyridine |
| JP2005511636A (ja) * | 2001-11-26 | 2005-04-28 | トラスティーズ オブ タフツ カレッジ | 自己免疫疾患の治療方法及びそれに関する試薬 |
| MY151015A (en) * | 2004-05-14 | 2014-03-31 | Takeda Pharmaceutical | Thienopyridine derivative, production method and use thereof |
| US7910592B2 (en) * | 2005-12-30 | 2011-03-22 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| WO2013072882A1 (en) | 2011-11-18 | 2013-05-23 | Actelion Pharmaceuticals Ltd | 2 -amino- 1, 8 -naphthyridine-3 -carboxamide derivatives as antimicrobial agents |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE225351T1 (de) | 1994-11-08 | 2002-10-15 | Takeda Chemical Industries Ltd | Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel |
| US5620997A (en) * | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU706110B2 (en) * | 1996-04-13 | 1999-06-10 | Astrazeneca Ab | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents |
| CA2249029A1 (en) | 1996-04-25 | 1997-10-30 | Haruhiko Makino | Thienopyridine derivatives and their use |
| EP1087977B1 (de) | 1998-06-15 | 2003-01-08 | Takeda Chemical Industries, Ltd. | Thienodipyridinderivate, ihre herstellung und verwendung |
| TW591031B (en) * | 2000-02-29 | 2004-06-11 | Takeda Chemical Industries Ltd | Thienopyridine derivatives, their production and use |
-
2001
- 2001-02-21 TW TW090103874A patent/TW591031B/zh not_active IP Right Cessation
- 2001-02-27 AR ARP010100880A patent/AR028511A1/es unknown
- 2001-02-28 HU HU0300028A patent/HUP0300028A3/hu unknown
- 2001-02-28 IL IL15108201A patent/IL151082A0/xx unknown
- 2001-02-28 SI SI200130281T patent/SI1259515T1/xx unknown
- 2001-02-28 PL PL01358015A patent/PL358015A1/xx not_active Application Discontinuation
- 2001-02-28 PT PT01908123T patent/PT1259515E/pt unknown
- 2001-02-28 US US10/204,593 patent/US6653476B2/en not_active Expired - Fee Related
- 2001-02-28 AU AU2001235985A patent/AU2001235985A1/en not_active Abandoned
- 2001-02-28 KR KR1020027010855A patent/KR100780584B1/ko not_active IP Right Cessation
- 2001-02-28 BR BR0108840-8A patent/BR0108840A/pt not_active Application Discontinuation
- 2001-02-28 NZ NZ520155A patent/NZ520155A/xx unknown
- 2001-02-28 ES ES01908123T patent/ES2227139T3/es not_active Expired - Lifetime
- 2001-02-28 CA CA002397165A patent/CA2397165A1/en not_active Abandoned
- 2001-02-28 DE DE60107055T patent/DE60107055T2/de not_active Expired - Fee Related
- 2001-02-28 CN CNB018058337A patent/CN1326859C/zh not_active Expired - Fee Related
- 2001-02-28 WO PCT/JP2001/001483 patent/WO2001064685A2/en active IP Right Grant
- 2001-02-28 DK DK01908123T patent/DK1259515T3/da active
- 2001-02-28 MX MXPA02008414A patent/MXPA02008414A/es unknown
- 2001-02-28 RU RU2002125854/04A patent/RU2002125854A/ru unknown
- 2001-02-28 EP EP01908123A patent/EP1259515B1/de not_active Expired - Lifetime
- 2001-02-28 CZ CZ20022511A patent/CZ20022511A3/cs unknown
- 2001-02-28 SK SK1071-2002A patent/SK10712002A3/sk unknown
- 2001-02-28 AT AT01908123T patent/ATE282042T1/de not_active IP Right Cessation
- 2001-02-28 JP JP2001054421A patent/JP3917821B2/ja not_active Expired - Fee Related
-
2002
- 2002-06-26 ZA ZA200205145A patent/ZA200205145B/en unknown
- 2002-08-28 NO NO20024107A patent/NO20024107L/no not_active Application Discontinuation
-
2003
- 2003-01-13 HK HK03100300.2A patent/HK1048120B/zh not_active IP Right Cessation
- 2003-09-03 US US10/662,165 patent/US7067527B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3420751B2 (ja) | 選択的ｃｏｘ‐２インヒビターとしてのピラゾロピリジン誘導体 | |
| ES2425739T3 (es) | Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal | |
| KR20220068987A (ko) | 아데노신 유도체 및 이를 포함하는 약학적 조성물 | |
| ES2469849T3 (es) | Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa | |
| WO2017184746A1 (en) | Nlrp3 modulators | |
| CA2084290A1 (en) | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases | |
| JP7493586B2 (ja) | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 | |
| IL139200A (en) | GASTRIC ACID SECRETION INHIBITING (N - SUBSTITUTED) IMIDAZO [1,2 - a] PYRIDINE - 6 - CARBOXAMIDES CARRYING A BENZYL GROUP IN POSITION 8, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND SOME INTERMEDIATES THEREFOR | |
| AU775993B2 (en) | Imidazopyridine derivatives as phosphodiesterase VII inhibitors | |
| ZA200100913B (en) | New compounds. | |
| KR20170105119A (ko) | 치환된 이미다조[1,2-a]피리딘-2-일아민 화합물, 및 약학 조성물 및 이의 사용 방법 | |
| JP2022537521A (ja) | 小分子標的ブロモ／アセチルタンパク質およびその使用 | |
| WO2020150115A1 (en) | Nlrp3 modulators | |
| TW202115083A (zh) | 肽醯精胺酸脫亞胺酶抑制劑及其用途 | |
| EA036965B1 (ru) | Ингибиторы деацетилаз гистонов и композиции и способы их применения | |
| RU2294935C2 (ru) | Имидазопиридиновые производные для применения в терапии в качестве лекарственного средства, ингибирующего протонный насос, и промежуточные соединения для их получения | |
| AU2011320651A1 (en) | HIV integrase inhibitors | |
| ZA200205145B (en) | Thienopyridine derivatives, their production and use. | |
| TW200808317A (en) | Compounds for treating pulmonary hypertension | |
| US20020111370A1 (en) | Compounds useful as antibacterial agents | |
| CA3217763A1 (en) | Tricyclic ubiquitin specific protease 1 inhibitor and use thereof | |
| CA2694994C (fr) | Derives de n-heteroaryl-carboxamides tricycliques, leur preparation et leur application en therapeutique | |
| JPH04173791A (ja) | 循環器系疾患の予防及び治療剤 | |
| EP4228630A1 (de) | Nlrp3-aktivatoren zur verwendung bei der behandlung von infektionskrankheiten oder krebs durch aktivierung von nlrp3-inflammasom | |
| AU2005289599A1 (en) | Crytalline forms of a pyrazolo [3, 4-c ] pyridine factor Xa inhibitor |